#novonordisk
$NOVO B (-17,74 %)
NovoNordisk is researching a new appetite suppressant preparation, Amycretinshowed impressive results in a Phase 1 study.
According to CNBC, a daily pill of amycretin within three months leads to a weight loss of up to 13% within three months.
The results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD). According to experts (an endocrinologist at Duke Health), the speed of weight loss with Amycretin outperforms other drugs, making the pill seem almost like a "miracle pill".
This data confirms earlier reports from Novo Nordisk and shows the potential of amylin-based drugs. Other Danish companies such as Zealand Pharma and Gubra are also working on similar programs. $NOVO B
